Stage-specific survival has improved for young breast cancer patients since 2000: but not equally
Open Access
- 1 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 182 (2), 477-489
- https://doi.org/10.1007/s10549-020-05698-z
Abstract
Purpose The stage-specific survival of young breast cancer patients has improved, likely due to diagnostic and treatment advances. We addressed whether survival improvements have reached all socioeconomic groups in a country with universal health care and national treatment guidelines. Methods Using Norwegian registry data, we assessed stage-specific breast cancer survival by education and income level of 7501 patients (2317 localized, 4457 regional, 233 distant and 494 unknown stage) aged 30-48 years at diagnosis during 2000-2015. Using flexible parametric models and national life tables, we compared excess mortality up to 12 years from diagnosis and 5-year relative survival trends, by education and income as measures of socioeconomic status (SES). Results Throughout 2000-2015, regional and distant stage 5-year relative survival improved steadily for patients with high education and high income (high SES), but not for patients with low education and low income (low SES). Regional stage 5-year relative survival improved from 85 to 94% for high SES patients (9% change; 95% confidence interval: 6, 13%), but remained at 84% for low SES patients (0% change; - 12, 12%). Distant stage 5-year relative survival improved from 22 to 58% for high SES patients (36% change; 24, 49%), but remained at 11% for low SES patients (0% change; - 19, 19%). Conclusions Regional and distant stage breast cancer survival has improved markedly for high SES patients, but there has been little survival gain for low SES patients. Socioeconomic status matters for the stage-specific survival of young breast cancer patients, even with universal health care.Funding Information
- Kreftforeningen (161326)
This publication has 45 references indexed in Scilit:
- Socioeconomic inequality in cancer survival – changes over time. A population-based study, Denmark, 1987–2013Acta Oncologica, 2019
- Stage-specific incidence and survival of breast cancer in Norway: The implications of changes in coding and classification practiceThe Breast, 2018
- Impact of national cancer policies on cancer survival trends and socioeconomic inequalities in England, 1996-2013: population based studyBMJ, 2018
- Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based studyEuropean Journal of Cancer Prevention, 2017
- Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trialsBreast Cancer Research and Treatment, 2015
- Biological markers of invasive breast cancerJapanese Journal of Clinical Oncology, 2015
- Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational TrialJournal of Clinical Oncology, 2011
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineThe Oncologist, 2009
- HerceptinPublished by Springer Science and Business Media LLC ,2008
- Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trialsSeminars in Oncology, 2001